Jo HE, et al. - Using the Australian IPF Registry, researchers analyzed prospectively collected data from patients with idiopathic pulmonary fibrosis (IPF) to examine the impact of the use of antacid therapy, gastroesophageal reflux disease (GORD) diagnosis and GORD symptoms, on survival and disease progression in IPF. Of the overall 684 patients in the registry, 587 (86%) qualified for inclusion in the study. According to the findings, longer term outcomes in IPF patients were not influenced by the use of antacid therapy nor by the presence of GORD symptoms. These findings add to the increasing evidence that IPF patients may not be benefitted with antacid therapy, and GORD directed therapy should be considered on an individual basis to treat the symptoms of reflux.